Literature DB >> 28510691

NF-κB upregulation through epigenetic silencing of LDOC1 drives tumor biology and specific immunophenotype in Group A ependymoma.

Andrea M Griesinger1, Davis A Witt1, Sydney T Grob1, Sabrina R Georgio Westover1, Andrew M Donson1, Bridget Sanford1, Jean M Mulcahy Levy1, Randall Wong1, Daniel C Moreira1, John A DeSisto1, Ilango Balakrishnan1, Lindsey M Hoffman1, Michael H Handler1, Kenneth L Jones1, Rajeev Vibhakar1, Sujatha Venkataraman1, Nicholas K Foreman1.   

Abstract

BACKGROUND: Inflammation has been identified as a hallmark of high-risk Group A (GpA) ependymoma (EPN). Chronic interleukin (IL)-6 secretion from GpA tumors drives an immune suppressive phenotype by polarizing infiltrating monocytes. This study determines the mechanism by which IL-6 is dysregulated in GpA EPN.
METHODS: Twenty pediatric GpA and 21 pediatric Group B (GpB) EPN had gene set enrichment analysis for MSigDB Hallmark gene sets performed. Protein and RNA from patients and cell lines were used to validate transcriptomic findings. GpA cell lines 811 and 928 were used for in vitro experiments performed in this study.
RESULTS: The nuclear factor-kappaB (NF-κB) pathway is a master regulator of IL-6 and a signaling pathway enriched in GpA compared with GpB EPN. Knockdown of NF-κB led to significant downregulation of IL-6 in 811 and 928. NF-κB activation was independent of tumor necrosis factor alpha (TNF-α) stimulation in both cell lines, suggesting that NF-κB hyperactivation is mediated through an alternative mechanism. Leucine zipper downregulated in cancer 1 (LDOC1) is a known transcriptional repressor of NF-κB. In many cancers, LDOC1 promoter is methylated, which inhibits gene transcription. We found decreased LDOC1 gene expression in GpA compared with GpB EPN, and in other pediatric brain tumors. EPN cells treated with 5AZA-DC, demethylated LDOC1 regulatory regions, upregulated LDOC1 expression, and concomitantly decreased IL-6 secretion. Stable knockdown of LDOC1 in EPN cell lines resulted in a significant increase in gene transcription of v-rel avian reticuloendotheliosis viral oncogene homolog A, which correlated to an increase in NF-κB target genes.
CONCLUSION: These results suggest that epigenetic silencing of LDOC1 in GpA EPN regulates tumor biology and drives inflammatory immune phenotype.
© The Author(s) 2017. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com

Entities:  

Keywords:  LDOC1; NF-κB; ependymoma; inflammation; methylation

Mesh:

Substances:

Year:  2017        PMID: 28510691      PMCID: PMC5596179          DOI: 10.1093/neuonc/nox061

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN: 1522-8517            Impact factor:   12.300


  28 in total

1.  Supratentorial clear cell ependymomas with branching capillaries demonstrate characteristic clinicopathological features and pathological activation of nuclear factor-kappaB signaling.

Authors:  Dominique Figarella-Branger; Emmanuèle Lechapt-Zalcman; Emeline Tabouret; Stephanie Jünger; André Maues de Paula; Corinne Bouvier; Carole Colin; Anne Jouvet; Fabien Forest; Felipe Andreiuolo; Isabelle Quintin-Roue; Marie-Christine Machet; Anne Heitzmann; Serge Milin; Henri Sevestre; Catherine Godfraind; François Labrousse; Philippe Metellus; Didier Scavarda; Torsten Pietsch
Journal:  Neuro Oncol       Date:  2016-03-15       Impact factor: 12.300

2.  Hedgehog-responsive candidate cell of origin for diffuse intrinsic pontine glioma.

Authors:  Michelle Monje; Siddhartha S Mitra; Morgan E Freret; Tal B Raveh; James Kim; Marilyn Masek; Joanne L Attema; Gordon Li; Terri Haddix; Michael S B Edwards; Paul G Fisher; Irving L Weissman; David H Rowitch; Hannes Vogel; Albert J Wong; Philip A Beachy
Journal:  Proc Natl Acad Sci U S A       Date:  2011-03-01       Impact factor: 11.205

Review 3.  Chemotherapy for intracranial ependymomas.

Authors:  E Bouffet; N Foreman
Journal:  Childs Nerv Syst       Date:  1999-10       Impact factor: 1.475

4.  LDOC1 mRNA is differentially expressed in chronic lymphocytic leukemia and predicts overall survival in untreated patients.

Authors:  Hatice Duzkale; Carmen D Schweighofer; Kevin R Coombes; Lynn L Barron; Alessandra Ferrajoli; Susan O'Brien; William G Wierda; John Pfeifer; Tadeusz Majewski; Bogdan A Czerniak; Jeffrey L Jorgensen; L Jeffrey Medeiros; Emil J Freireich; Michael J Keating; Lynne V Abruzzo
Journal:  Blood       Date:  2011-02-10       Impact factor: 22.113

5.  Interleukin-6/STAT3 Pathway Signaling Drives an Inflammatory Phenotype in Group A Ependymoma.

Authors:  Andrea M Griesinger; Rebecca J Josephson; Andrew M Donson; Jean M Mulcahy Levy; Vladimir Amani; Diane K Birks; Lindsey M Hoffman; Steffanie L Furtek; Phillip Reigan; Michael H Handler; Rajeev Vibhakar; Nicholas K Foreman
Journal:  Cancer Immunol Res       Date:  2015-05-12       Impact factor: 11.151

6.  Delineation of two clinically and molecularly distinct subgroups of posterior fossa ependymoma.

Authors:  Hendrik Witt; Stephen C Mack; Marina Ryzhova; Sebastian Bender; Martin Sill; Ruth Isserlin; Axel Benner; Thomas Hielscher; Till Milde; Marc Remke; David T W Jones; Paul A Northcott; Livia Garzia; Kelsey C Bertrand; Andrea Wittmann; Yuan Yao; Stephen S Roberts; Luca Massimi; Tim Van Meter; William A Weiss; Nalin Gupta; Wiesia Grajkowska; Boleslaw Lach; Yoon-Jae Cho; Andreas von Deimling; Andreas E Kulozik; Olaf Witt; Gary D Bader; Cynthia E Hawkins; Uri Tabori; Abhijit Guha; James T Rutka; Peter Lichter; Andrey Korshunov; Michael D Taylor; Stefan M Pfister
Journal:  Cancer Cell       Date:  2011-08-16       Impact factor: 31.743

7.  A prognostic gene expression signature in infratentorial ependymoma.

Authors:  Khalida Wani; Terri S Armstrong; Elizabeth Vera-Bolanos; Aditya Raghunathan; David Ellison; Richard Gilbertson; Brian Vaillant; Stewart Goldman; Roger J Packer; Maryam Fouladi; Ian Pollack; Tom Mikkelsen; Michael Prados; Antonio Omuro; Riccardo Soffietti; Alicia Ledoux; Charmaine Wilson; Lihong Long; Mark R Gilbert; Ken Aldape
Journal:  Acta Neuropathol       Date:  2012-02-10       Impact factor: 17.088

8.  Epigenetic silencing of the LDOC1 tumor suppressor gene in ovarian cancer cells.

Authors:  Marie-Luise Buchholtz; Ansgar Brüning; Ioannis Mylonas; Julia Jückstock
Journal:  Arch Gynecol Obstet       Date:  2014-02-21       Impact factor: 2.344

9.  Multifactorial analysis of predictors of outcome in pediatric intracranial ependymoma.

Authors:  Lee Ridley; Ruman Rahman; Marie-Anne Brundler; David Ellison; James Lowe; Keith Robson; Emma Prebble; Inga Luckett; Richard J Gilbertson; Sheila Parkes; Vikki Rand; Beth Coyle; Richard G Grundy
Journal:  Neuro Oncol       Date:  2008-08-13       Impact factor: 12.300

10.  Current treatment options for pediatric and adult patients with ependymoma.

Authors:  Karen D Wright; Amar Gajjar
Journal:  Curr Treat Options Oncol       Date:  2012-12
View more
  10 in total

1.  Specific expression of PD-L1 in RELA-fusion supratentorial ependymoma: Implications for PD-1-targeted therapy.

Authors:  Davis A Witt; Andrew M Donson; Vladimir Amani; Daniel C Moreira; Bridget Sanford; Lindsey M Hoffman; Michael H Handler; Jean M Mulcahy Levy; Kenneth L Jones; Anandani Nellan; Nicholas K Foreman; Andrea M Griesinger
Journal:  Pediatr Blood Cancer       Date:  2018-01-19       Impact factor: 3.167

2.  Establishment of patient-derived orthotopic xenograft model of 1q+ posterior fossa group A ependymoma.

Authors:  Angela M Pierce; Davis A Witt; Andrew M Donson; Ahmed Gilani; Bridget Sanford; Martin Sill; Benjamin Van Court; Ayman Oweida; Eric W Prince; Jenna Steiner; Etienne Danis; Kathleen Dorris; Todd Hankinson; Michael H Handler; Kenneth L Jones; Sana D Karam; Natalie J Serkova; Rajeev Vibhakar; Nicholas K Foreman; Andrea M Griesinger
Journal:  Neuro Oncol       Date:  2019-12-17       Impact factor: 12.300

3.  Pro-inflammatory cytokines mediate the epithelial-to-mesenchymal-like transition of pediatric posterior fossa ependymoma.

Authors:  Rachael G Aubin; Emma C Troisi; Javier Montelongo; Adam N Alghalith; Maclean P Nasrallah; Mariarita Santi; Pablo G Camara
Journal:  Nat Commun       Date:  2022-07-08       Impact factor: 17.694

Review 4.  The biology of ependymomas and emerging novel therapies.

Authors:  Amr H Saleh; Nardin Samuel; Kyle Juraschka; Mohammad H Saleh; Michael D Taylor; Michael G Fehlings
Journal:  Nat Rev Cancer       Date:  2022-01-14       Impact factor: 69.800

Review 5.  Improving Diagnostic and Therapeutic Outcomes in Pediatric Brain Tumors.

Authors:  Sydney T Grob; Jean M Mulcahy Levy
Journal:  Mol Diagn Ther       Date:  2018-02       Impact factor: 4.074

6.  Single-Cell RNA Sequencing of Childhood Ependymoma Reveals Neoplastic Cell Subpopulations That Impact Molecular Classification and Etiology.

Authors:  Austin E Gillen; Kent A Riemondy; Vladimir Amani; Andrea M Griesinger; Ahmed Gilani; Sujatha Venkataraman; Krishna Madhavan; Eric Prince; Bridget Sanford; Todd C Hankinson; Michael H Handler; Rajeev Vibhakar; Ken L Jones; Siddhartha Mitra; Jay R Hesselberth; Nicholas K Foreman; Andrew M Donson
Journal:  Cell Rep       Date:  2020-08-11       Impact factor: 9.423

7.  Discriminating Origin Tissues of Tumor Cell Lines by Methylation Signatures and Dys-Methylated Rules.

Authors:  Shiqi Zhang; Tao Zeng; Bin Hu; Yu-Hang Zhang; Kaiyan Feng; Lei Chen; Zhibin Niu; Jianhao Li; Tao Huang; Yu-Dong Cai
Journal:  Front Bioeng Biotechnol       Date:  2020-05-26

8.  Investigation of miRNA and mRNA Co-expression Network in Ependymoma.

Authors:  Feili Liu; Hang Dong; Zi Mei; Tao Huang
Journal:  Front Bioeng Biotechnol       Date:  2020-03-19

9.  Genomic Landscape of Intramedullary Spinal Cord Gliomas.

Authors:  Ming Zhang; Rajiv R Iyer; Tej D Azad; Qing Wang; Tomas Garzon-Muvdi; Joanna Wang; Ann Liu; Peter Burger; Charles Eberhart; Fausto J Rodriguez; Daniel M Sciubba; Jean-Paul Wolinsky; Ziya Gokaslan; Mari L Groves; George I Jallo; Chetan Bettegowda
Journal:  Sci Rep       Date:  2019-12-10       Impact factor: 4.379

Review 10.  Molecular Classification and Therapeutic Targets in Ependymoma.

Authors:  Thomas Larrew; Brian Fabian Saway; Stephen R Lowe; Adriana Olar
Journal:  Cancers (Basel)       Date:  2021-12-10       Impact factor: 6.639

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.